Teva Raises Guidance Amid Generics Growth
Firm Is Actively Examining BD Opportunities; Also Provides Update On Israel Conflict
Executive Summary
Teva management sounded an optimistic note as the firm delivered its third-quarter results for 2023, adding a further $100m to the company’s full-year sales forecast and providing updates on a number of key aspects of the business.
You may also be interested in...
Teva Delivers First US Forteo Equivalent
Teva has celebrated a US nod for its generic version of Forteo, the first substitutable teriparatide rival to be approved by the US Food and Drug Administration.
Generic Revlimid Flounders Amid Successful Q2 Performance At Sun
Sun delivered an exceptional Q2 performance, marred by a 9% decline in its US business due to a significant drop in lenalidomide sales.
Who’s Hired? Ananth Returns To Teva As New API Chief
Teva has announced that R. Ananthanarayanan – known as Ananth – is to rejoin the company as CEO of its active pharmaceutical ingredients business after taking leading roles at Cipla and Strides in recent years. Meanwhile, Strides has disclosed a change of chief operating officer coming next year, while Civica Rx has named a manager for its sterile injectables operations.